Abstract Number: 506 • 2017 ACR/ARHP Annual Meeting
The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol
Background/Purpose: Upadacitinib is a selective JAK1 inhibitor being developed for the treatment of several inflammatory diseases, including rheumatoid arthritis (RA). Upadacitinib showed favorable efficacy and…Abstract Number: 519 • 2017 ACR/ARHP Annual Meeting
Filgotinib, a Selective Janus Kinase 1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects
Background/Purpose: Filgotinib is a potent and selective Janus kinase 1 (JAK1) inhibitor being developed to treat inflammatory diseases. Safety pharmacology studies and Phase 1 studies…Abstract Number: 646 • 2016 ACR/ARHP Annual Meeting
Population Pharmacokinetics of ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A: Analyses Across Phase 1 Studies in Healthy Volunteers and Phase 2 Studies in Subjects with Rheumatoid or Psoriatic Arthritis
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…Abstract Number: 1594 • 2016 ACR/ARHP Annual Meeting
First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Background/Purpose: Spleen Tyrosine Kinase (SYK) mediates immunoreceptor signaling in a range of hematopoietic cells important for the initiation and progression of inflammatory diseases such as…Abstract Number: 1604 • 2016 ACR/ARHP Annual Meeting
a First-in-Human Study of CR6086, a New Potent EP4 Prostanoid Receptor Antagonist, Demonstrates Good Safety and Tolerability at Therapeutically Relevant Exposures
Background/Purpose: CR6086 is a potent and selective antagonist of the prostaglandin EP4 receptor. EP4 receptors have a role in T-cell differentiation and expansion, and thus…Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…Abstract Number: 1629 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics of ABT-494 with the Once-Daily Extended-Release Tablet Formulation Being Utilized in the Ongoing Rheumatoid Arthritis Phase 3 Trials
Background/Purpose: ABT-494 is a selective Janus Kinase 1 inhibitor. In two Phase 2b studies in subjects with rheumatoid arthritis, 6 mg and 12 mg twice-daily…Abstract Number: 3014 • 2016 ACR/ARHP Annual Meeting
Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis
Background/Purpose: Treatment with biologicals is based on the principle of ‘one size fits all’ without taking differences into account for dosing schemes, patients’ characteristics and…Abstract Number: 2727 • 2015 ACR/ARHP Annual Meeting
BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
Background/Purpose: BI 695501 is a proposed adalimumab biosimilar currently in development and was evaluated for pharmacokinetic (PK) similarity to both US-licensed and EU-approved reference products.…
ACR Meeting Abstracts